ESPAC-4
Combination versus single agent chemotherapy in resectable pancreatic ductal and ampullary cancers.
ESPAC-4
Combination versus single agent chemotherapy in resectable pancreatic ductal and ampullary cancers.
| Funding | CR:UK |
| Portfolio | Cancer |
| Interventions | Medicine |
| Randomised | True |
| Status | In Follow-up |
| Start Date | 13-Oct-2008 |
Long term survival following resection for pancreatic cancer still needs to be improved. Adjuvant 5-FU/FA demonstrates significant improvement in overall survival following Surgery, adjuvant gemcitabine demonstrates a survival advantage following surgical resection for pancreatic cancer. Gemcitabine plus capecitabine improves survival in patients with advanced pancreatic cancer compared with single agent gemcitabine
Publications
- Springfeld C, Jäger D, Büchler MW, Strobel O, Hackert T, Palmer DH, Neoptolemos JP. Chemotherapy for pancreatic cancer. Presse Med. 2019 Mar 14. pii: S0755-4982(19)30074-0. doi: 10.1016/j.lpm.2019.02.025. [Epub ahead of print] PubMed PMID: 30879894